Vimarsana
Biggest News Aggregation in the World

Page 8 - Hartmutj Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hartmutj Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hartmutj Ehrlich Today - Breaking & Trending Today

Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference - Vimarsana News

Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference

EQS-News: ABIVAX / Key word(s): ConferenceAbivax to attend the J.P. Morgan 41st Annual Healthcare Conference 14.12.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX TO ATTEND THE J.P. MORGAN 41ST ANNUAL HEALTHCARE CONFERENCEAbivax’s senior executive management wil...

Abivax to Attend the J.P. Morgan 41st Annual Healthcare Conference - Vimarsana News

Abivax to Attend the J.P. Morgan 41st Annual Healthcare Conference

Abivax's senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event from January 9-12 in San Francisco, USPARIS

First US patient enrolled in Abivax's phase 3 trial of obefazimod for ulcerative colitis - Vimarsana News

First US patient enrolled in Abivax's phase 3 trial of obefazimod for ulcerative colitis

Abivax announced that the first U.S. patient has been enrolled in its global phase 3 clinical trial of its oral small-molecule inhibitor obefazimod for the treatment of moderate to severe ulcerative colitis. The trial will include two induction studies – ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106) – and a subsequent ABTECT maintenance trial (ABX464-107) that will investigate 25

Source: healio.com
ABIVAX: First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis - Vimarsana News

ABIVAX: First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US1,200 UC patients across 36 countries

DGAP-News: Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology - Vimarsana News

DGAP-News: Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology

DGAP-News: ABIVAX / Key word(s): Study Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the La...